What happened
Kardi Ai announced a CZK 130 million Series A financing round on 11 November 2026, led by German health‑technology venture fund Callisto Health. The round valued the company at CZK 600 million post‑money. Existing investors – the Seed Starter programs of Česká spořitelna and Slovenská sporiteľňa, BrightCap Ventures, Purple Ventures, DEPO Ventures and Garage Angels – also participated. The capital will fund geographic expansion into Germany, India, the UAE and Southeast Asia, and support development of AI models that predict arrhythmia risk beyond the current long‑term ECG monitoring service.
On 11 November 2026, Kardi Ai disclosed that it had closed a CZK 130 million (approximately $5.3 million) Series A round. The round was led by Callisto Health, a German venture fund focused on health‑technology, and included participation from the Seed Starter programs of Česká spořitelna and Slovenská sporiteľňa, as well as several early‑stage investors that have backed Kardi Ai since its pre‑seed round in 2022. The financing brings the company’s post‑money valuation to CZK 600 million.
The company plans to allocate the funds to three main areas: (1) geographic expansion into Germany, India, the United Arab Emirates and Southeast Asian markets; (2) scaling its existing ECG‑monitoring service, which combines a chest‑strap sensor, a mobile app and AI‑driven analysis; and (3) developing and clinically validating new AI models that estimate a patient’s risk of future arrhythmia events based on longitudinal ECG data.
Kardi Ai currently operates in Czechia, Slovakia, Poland, Romania and Bulgaria, with more than 70 hospital partners and over 6,000 active users. Approximately 25 % of monitored users have received alerts for possible arrhythmias, and more than 500 of those alerts have been classified as critical by clinicians. The company holds a medical‑device registration certificate from the UAE Ministry of Health and Prevention and has secured an MD‑15 import licence from India’s CDSCO, positioning it for market entry later in 2026.
Why it matters
Kardi Ai’s blend of wearable ECG hardware, a mobile app and AI analysis targets a growing need for continuous cardiac monitoring that can detect intermittent arrhythmias missed by short clinical exams. By scaling the solution across multiple markets, the company could increase access to early‑warning cardiac care for millions, especially in regions where specialist cardiology services are scarce. The announced predictive‑risk models, if validated and approved, would move the product from passive monitoring to proactive risk stratification, potentially reducing emergency cardiac events and associated healthcare costs. The sizable Series A, the largest for a Czech med‑tech startup to date, signals strong investor confidence in AI‑enabled remote diagnostics and may encourage further capital flow into similar health‑AI ventures in Central and Eastern Europe.
Continuous cardiac monitoring using AI can capture intermittent arrhythmias that are often missed during brief clinical examinations, offering a pathway to earlier diagnosis and treatment. Kardi Ai’s platform, which is already deployed in several Central and Eastern European health systems, demonstrates that AI‑enhanced wearables can be integrated into routine care without requiring extensive new infrastructure.
The announced predictive‑risk models aim to shift the product from reactive monitoring to proactive risk assessment. If validated, such models could enable clinicians to intervene before an arrhythmia manifests, potentially reducing emergency admissions and improving patient outcomes. This represents a significant step toward AI‑driven preventive cardiology.
The size of the Series A round, the largest for a Czech med‑tech startup, underscores growing investor appetite for AI‑powered health solutions in emerging European markets. It may catalyze further venture activity in the region, encouraging other startups to pursue AI integration in medical devices.
Regulatory pathways remain a major hurdle. The company must obtain CE‑marking for its predictive models in the EU and secure approvals in India, the UAE and Singapore. Successful navigation of these processes will set precedents for other AI‑based diagnostic tools seeking cross‑border clearance.
Interactive Mechanism: How It Actually Works
Explore the underlying technology behind this development interactively.
Which component of an AI application is the machine-learning model itself?
What to watch next
Key upcoming milestones include regulatory clearance for the predictive‑risk models in the EU, India, UAE and Singapore, and the launch of the German market after pilot completion. Observers should track the performance of the AI algorithms in real‑world settings, especially the false‑positive rate of arrhythmia alerts, which will affect clinician adoption. The company’s ability to secure partnerships with hospitals and insurers in new regions will also determine whether the expansion translates into sustainable revenue. Finally, any updates on pricing, reimbursement pathways, or integration with electronic health‑record systems will be critical for assessing commercial viability.
Regulatory approvals: The timeline for CE‑marking of the predictive‑risk models in the EU, as well as approvals from India’s CDSCO, the UAE Ministry of Health, and Singapore’s Health Sciences Authority, will be decisive for market rollout.
Clinical validation results: Independent studies confirming the accuracy, sensitivity and specificity of the AI alerts and risk‑prediction algorithms will influence physician trust and adoption rates.
Pricing and reimbursement: Information on pricing structures, insurance coverage, or government reimbursement schemes in new markets will affect the platform’s commercial scalability.
Partnerships and distribution: The formation of local distributor agreements, especially in Germany and India, and collaborations with hospital networks or corporate wellness programs will be key indicators of market penetration.
User experience and data privacy: How Kardi Ai handles patient data across jurisdictions, particularly under GDPR and India’s data‑protection regulations, will be scrutinized by regulators and users alike.